Next-Generation Direct-Acting Antiviral Drug-Based Regimens for Hepatitis C

Next-Generation Direct-Acting Antiviral Drug-Based Regimens for Hepatitis C Curr Hepatology Rep (2017) 16:184–191 DOI 10.1007/s11901-017-0351-0 HEPATITIS C (J AHN AND A ARONSOHN, SECTION EDITORS) Next-Generation Direct-Acting Antiviral Drug-Based Regimens for Hepatitis C 1,2 1,3,4 1,3,4 Isaac Ruiz & Stéphane Chevaliez & Jean-Michel Pawlotsky Published online: 25 July 2017 Springer Science+Business Media, LLC 2017 Abstract to-use, highly efficient, pangenotypic, once-daily, all-oral, Purpose of Review This article reviews the most recent results interferon- and ribavirin-free. of clinical trials supporting the approval and use of the so-called . . next-generation hepatitis C virus (HCV) direct-acting antiviral Keywords Hepatitis C virus Direct-acting antiviral drugs (DAA) drug regimens, including glecaprevir/pibrentasvir, Next-generation regimens Resistance-associated sofosbuvir/velpatasvir/voxilaprevir, uprifosbuvir/grazoprevir/ substitutions ruzasvir, and AL-335/simeprevir/odalasvir. Recent Findings From 2014 and onwards, HCV DAA drugs belonging to four classes were approved in Europe and the Introduction USA. These combinations are generally safe and well tolerat- ed and yield high rates of sustained virological response Hepatitis C virus (HCV) infection represents a major public (>95%) in most patient populations. However, there is a need health problem, with over 71 million persons chronically infect- for treatment simplification and efficacy in difficult-to-cure ed worldwide [1� ]. The primary goal of HCV therapy is to cure patient populations. Phase II and III clinical http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Hepatology Reports Springer Journals

Next-Generation Direct-Acting Antiviral Drug-Based Regimens for Hepatitis C

Loading next page...
 
/lp/springer_journal/next-generation-direct-acting-antiviral-drug-based-regimens-for-xAEqULo0xW
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Hepatology
eISSN
2195-9595
D.O.I.
10.1007/s11901-017-0351-0
Publisher site
See Article on Publisher Site

Abstract

Curr Hepatology Rep (2017) 16:184–191 DOI 10.1007/s11901-017-0351-0 HEPATITIS C (J AHN AND A ARONSOHN, SECTION EDITORS) Next-Generation Direct-Acting Antiviral Drug-Based Regimens for Hepatitis C 1,2 1,3,4 1,3,4 Isaac Ruiz & Stéphane Chevaliez & Jean-Michel Pawlotsky Published online: 25 July 2017 Springer Science+Business Media, LLC 2017 Abstract to-use, highly efficient, pangenotypic, once-daily, all-oral, Purpose of Review This article reviews the most recent results interferon- and ribavirin-free. of clinical trials supporting the approval and use of the so-called . . next-generation hepatitis C virus (HCV) direct-acting antiviral Keywords Hepatitis C virus Direct-acting antiviral drugs (DAA) drug regimens, including glecaprevir/pibrentasvir, Next-generation regimens Resistance-associated sofosbuvir/velpatasvir/voxilaprevir, uprifosbuvir/grazoprevir/ substitutions ruzasvir, and AL-335/simeprevir/odalasvir. Recent Findings From 2014 and onwards, HCV DAA drugs belonging to four classes were approved in Europe and the Introduction USA. These combinations are generally safe and well tolerat- ed and yield high rates of sustained virological response Hepatitis C virus (HCV) infection represents a major public (>95%) in most patient populations. However, there is a need health problem, with over 71 million persons chronically infect- for treatment simplification and efficacy in difficult-to-cure ed worldwide [1� ]. The primary goal of HCV therapy is to cure patient populations. Phase II and III clinical

Journal

Current Hepatology ReportsSpringer Journals

Published: Jul 25, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off